Annual Meeting Highlights

ASH 2016 Annual Meeting Highlights in Hodgkin Lymphoma
ASH 2016 Annual Meeting Highlights in Hodgkin Lymphoma
CME, CPE, CNE
Stephen M. Ansell, MD, PhD; Bruce D. Cheson, MD, FACP, FAAS; Martin Hutchings, MD, PhD; Alison J. Moskowitz, MD
Release Date: December 19, 2016
Expiration Date: December 19, 2017
In this activity, participants will learn about key highlights of the most impactful and groundbreaking data in Hodgkin lymphoma (HL), presented at the 2016 American Society of Hematology (ASH) annual meeting. Leading experts in the field of HL will share their insights on a variety of abstracts, covering topics including, but not limited to: anti-CD30 therapy, immunotherapy, PET-adapted therapy, and predictive biomarkers.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Takeda Oncology.
Begin, Earn CreditView Only, No Credit
 
10th ISHL Highlights
10th ISHL Highlights
CME, CPE, CNE
Pauline Brice, MD; Paul Bröckelmann, MD; Andreas Engert, MD; Martin Hutchings, MD, PhD; and Alison J. Moskowitz, MD
Release Date: November 18, 2016
Expiration Date: November 18, 2017
In this activity, leading experts will provide highlights of various educational sessions and the latest clinical data presented at ISHL, giving participants the opportunity to remain up-to-date on advances in Hodgkin lymphoma.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Takeda Oncology.
Begin, Earn CreditView Only, No Credit
 
2016 EHA Annual Meeting Highlights in HL
2016 EHA Annual Meeting Highlights in HL
CME, CPE, CNE
Peter Borchmann, MD; Paul Bröckelmann, MD; Astrid Pavlovsky, MD; and Anas Younes, MD
Release Date: July 06, 2016
Expiration Date: July 06, 2017
The European Hematology Association (EHA) 2016 Annual Meeting highlights for Hodgkin lymphoma covers the most exciting and clinically relevant data presented at the conference. A group of expert faculty, including Dr. Peter Borchmann, Dr. Paul Bröckelmann, Dr. Astrid Pavlovsky, and Dr. Anas Younes, provide overviews of data spanning topics such as, immuno-oncology, PET-adapted therapy, real-world use of brentuximab vedotin and data from the German Hodgkin Study Group, while sharing insights into the impact of these data on clinical practice.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Takeda Oncology.
Begin, Earn CreditView Only, No Credit
 

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2017 MediCom Worldwide, Inc. All rights reserved